
    
      This multicenter study in previously pexidartinib-treated participants with TGCT will provide
      the Investigators and participants the option at Screening to either continue pexidartinib
      treatment (Treatment Continuation Cohort) or discontinue treatment with the possibility of
      re-initiating pexidartinib treatment (Treatment-Free/Re-Treatment Cohort).
    
  